| Indicators | Browse All

Ernexa Therapeutics Inc. (ERNA)

Healthcare | Biotechnology | Cambridge, United States | NasdaqCM
6.06 USD +0.52 (9.386%) ⇧ (July 14, 2026, 4 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:52 a.m. EDT

The immediate outlook is clouded by severe technical damage and a lack of institutional support. Despite a recent spike driven by ovarian cancer trial news, the stock remains deeply trapped below its 50-day and 200-day moving averages, indicating that the broader market view remains overwhelmingly negative. The statistical forecast model offers no directional edge, reflecting the chaotic nature of such volatile biotech plays. Fundamentally, the business is in a state of collapse; it has lost 99.95% of its value over the last nine years, with four consecutive years of negative annual returns ending in a sharp decline. The balance sheet shows massive losses and negative returns on equity, while the forward P/E is meaningless due to negative earnings. There is no dividend to provide income, and the company is burning cash rapidly. While the clinical trial data may offer a theoretical catalyst for a recovery, the current price action and deteriorating fundamentals suggest the market is pricing in a continued struggle rather than an imminent turnaround.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.737601
MSTL0.750656
AutoTheta1.053987
AutoARIMA1.065259

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 32%
H-stat 0.29
Ljung-Box p 0.000
Jarque-Bera p 0.371
Excess Kurtosis -0.76
Attribute Value
Sector Healthcare
Debt to Equity Ratio 5.671
Market Cap 7,067,978
Trailing P/E 0.00
Forward P/E -0.63
Beta 2.51
Previous Name NTN Buzztime, Inc
Website https://www.ernexatx.com

Info Dump

Attribute Value
52 Week Change -0.88458335
Address1 1,035 Cambridge Street
Address2 Suite 18A
All Time High 8,625,000.0
All Time Low 3.18
Ask 7.53
Ask Size 2
Average Daily Volume10 Day 24,040
Average Daily Volume3 Month 1,675,464
Average Volume 1,675,464
Average Volume10Days 24,040
Beta 2.509
Bid 4.25
Bid Size 2
Book Value 5.882
City Cambridge
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 6.06
Current Ratio 2.892
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 6.15
Day Low 5.7719
Debt To Equity 5.671
Display Name Ernexa Therapeutics
Earnings Timestamp End 1,755,288,000
Earnings Timestamp Start 1,754,942,400
Ebitda -10,080,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.171
Enterprise Value -1,719,022
Eps Forward -9.6
Eps Trailing Twelve Months 1,214.25
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 7.795
Fifty Day Average Change -1.7350001
Fifty Day Average Change Percent -0.22257859
Fifty Two Week Change Percent -88.458336
Fifty Two Week High 71.5
Fifty Two Week High Change -65.44
Fifty Two Week High Change Percent -0.9152448
Fifty Two Week Low 3.18
Fifty Two Week Low Change 2.8799999
Fifty Two Week Low Change Percent 0.90566033
Fifty Two Week Range 3.18 - 71.5
Financial Currency USD
First Trade Date Milliseconds 683,472,600,000
Float Shares 668,717
Forward Eps -9.6
Forward P E -0.63124996
Free Cashflow -10,014,250
Full Exchange Name NasdaqCM
Full Time Employees 5
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.41742
Held Percent Institutions 0.10158
Implied Shares Outstanding 1,166,333
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,777,852,800
Last Split Factor 1:25
Long Business Summary Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Long Name Ernexa Therapeutics Inc.
Market us_market
Market Cap 7,067,978
Market State PRE
Max Age 86,400
Message Board Id finmb_24349026
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-15
Net Income To Common -11,404,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 6,461,484
Number Of Analyst Opinions 1
Open 5.89
Operating Cashflow -7,216,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 617 798 6700
Prev Name NTN Buzztime, Inc
Previous Close 5.54
Price Hint 2
Price To Book 1.0302618
Profit Margins 0.0
Quick Ratio 2.682
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.52
Regular Market Change Percent 9.386282
Regular Market Day High 6.15
Regular Market Day Low 5.7719
Regular Market Day Range 5.7719 - 6.15
Regular Market Open 5.89
Regular Market Previous Close 5.54
Regular Market Price 6.06
Regular Market Time 1,784,059,201
Regular Market Volume 18,781
Return On Assets -0.812
Return On Equity -25.05611
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 1,166,333
Shares Percent Shares Out 0.0252
Shares Short 29,381
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 44,811
Short Name Ernexa Therapeutics Inc.
Short Percent Of Float 0.04
Short Ratio 0.5
Source Interval 15
State MA
Symbol ERNA
Target High Price 30.0
Target Low Price 30.0
Target Mean Price 30.0
Target Median Price 30.0
Total Cash 9,177,000
Total Cash Per Share 7.868
Total Debt 389,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 1,214.25
Trailing P E 0.004990735
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 18.92375
Two Hundred Day Average Change -12.86375
Two Hundred Day Average Change Percent -0.6797675
Type Disp Equity
Volume 18,781
Website https://www.ernexatx.com
Zip 2,141